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Radiotherapy for the treatment of cancer in companion animals is currently administered by using megavoltage X-ray machines. Because 
these machines are expensive, most animal hospitals do not perform radiotherapy. This study evaluated the ability of relatively inexpensive 
kilovoltage X-ray machines to treat companion animals. A simulation study based on a commercial treatment-planning system was performed 
for tumors of the brain (non-infectious meningoencephalitis), nasal cavity (malignant nasal tumors), forefoot (malignant muscular tumors), 
and abdomen (malignant intestinal tumors). The results of kilovoltage (300 kV and 450 kV) and megavoltage (6 MV) X-ray beams were 
compared. Whereas the 300 kV and 6 MV X-ray beams provided optimal radiation dose homogeneity and conformity, respectively, for brain 
tumors, the 6 MV X-rays provided optimal homogeneity and radiation conformity for nasal cavity, forefoot, and abdominal tumors. Although 
megavoltage X-ray beams provided better radiation dose distribution in most treated animals, the differences between megavoltage and 
kilovoltage X-ray beams were relatively small. The similar therapeutic effects of the kilovoltage and 6 MV X-ray beams suggest that 
kilovoltage X-ray beams may be effective alternatives to megavoltage X-ray beams in treating cancers in companion animals.
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Introduction
Radiotherapy is important in cancer treatment [6], including 
the treatment of cancer in companion animals. For example, 
radiotherapy has prolonged survival in dogs with nasal 
adenocarcinomas, when compared with results from surgery or 
chemotherapy [12]. Moreover, radiotherapy, both alone and in 
combination with surgery, has produced good therapeutic 
outcomes in animals with intracranial meningiomas [2], and 
radiotherapy has provided excellent therapeutic efficacy for 
animals with difficult-to-treat mandibular squamous cell 
carcinomas and genitourinary carcinomas [3,4,7,11,13,23,26].
Although the incidence of cancer is generally higher in 
companion animals than in humans [8,9,25,27], methods of 
treating cancers in companion animals are limited [20]. 
Radiotherapy of companion animals usually involves the use of 
a linear accelerator designed to treat humans. Clinical linear 
accelerators accelerate electrons by using high-frequency 
electromagnetic waves, producing high-energy X-ray beams 
when the electrons hit their target. Although these X-rays are 
effective in treating deeply located tumors, the use of these 
devices to treat cancers in companion animals is limited by their 
large size, high cost, and complicated protocols. Moreover, 
these devices require shielding to protect people in the vicinity 
against high-energy radiation. At present, few animal hospitals 
in the USA, Europe, and Japan use linear accelerators to treat 
companion animals.
Tumors are generally located at a shallower depth in 
companion animals than in humans, largely because these 
animals are smaller. Because X-ray beams in animals are not 
required to penetrate as deeply as the high-energy high-penetration 
beams used to treat human cancers, lower energy X-ray beams 
may be sufficient to treat cancers in these animals. Kilovoltage 
X-ray beams of 150 to 500 kV may be effective for treating 
cancers in animals. These beams require less energy than 
conventional megavoltage X-ray beams used to treat human 
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Fig. 1. Percentage depth doses (PDD) of 
300 kV, 450 kV, and 6 MV X-ray beams at 
field sizes of (A) 3 cm × 3 cm, (B) 6 cm × 
6 cm, (C) 10 cm × 10 cm, (D) 15 cm × 
15 cm, and (E) 20 cm × 20 cm.
Table 1. Treatment plan information, including the numbers of 
fields and the use of wedges and boluses, for each tumor site and 
X-ray beam energy
Tumor 
site
Energy
No. of 
fields
Usage of 
wedge
Usage of 
bolus
Brain 300 kV, 
450 kV, 
and 6 MV
6 No No
Nasal 300 kV 
and 450 kV
6 No No
6 MV 5 Yes 
(15o wedges)
No
Forefoot 300 kV 
and 450 kV
6 No No
6 MV 6 No Yes 
(1.5 cm thick)
Abdomen 300 kV, 
450 kV, 
and 6 MV
6 No No
cancers and do not require a device to create microwaves, 
making kilovoltage devices easier to manufacture and more 
cost-effective. In addition, kilovoltage devices are smaller and 
require less shielding than megavoltage devices, making 
kilovoltage devices easier to install. In this study, a commercial 
treatment-planning system was used to simulate treatment of 
various tumors in dogs with 300 kV, 450 kV, and 6 MV X-ray 
beams. The ability of kilovoltage X-ray machines to treat 
companion animals was evaluated by comparing the results of 
kilovoltage and megavoltage X-ray beam treatment.
Materials and Methods
Determining percentage depth radiation dose for 300 kV 
and 450 kV X-ray beams
GATE is an advanced, open-source software used for 
numerical simulations in medical imaging and radiotherapy 
[5,16,29,30]. To simulate radiation treatment using kilovoltage 
X-ray beams, the dependence of radiation dose distribution on 
depth, a parameter called percentage depth dose (PDD) [19], 
was calculated for the 300 kV and 450 kV X-ray beams by using 
GATE software (ver. 7.2). X-ray beams were generated by 300 
kV [21] and 450 kV [22] X-ray point sources and passed 
through a filter and collimator into a water phantom. A 2-mm 
aluminum filter was used for the 300 kV X-ray beam and a 
Thoraeus III filter (0.6 mm tin + 0.25 mm copper + 1 mm 
aluminum) for the 450 kV X-ray beam. The water phantom had 
dimensions of 100 cm × 100 cm × 100 cm, and the PDD was 
calculated for five irradiation field sizes (3 cm × 3 cm, 6 cm × 
6 cm, 10 cm × 10 cm, 15 cm × 15 cm, and 20 cm × 20 cm).
Radiotherapy treatment planning
The commercial Core-PLAN (Seoul C&J, Korea) 
treatment-planning system [17,18] calculates predicted 
radiation doses using the equivalent tissue-air ratio and 
collapsed cone convolution algorithms. In the present study, 
Core-PLAN (ver. 3.5.0.5) was used to calculate the predicted 
radiation doses for four tumor locations in dogs: brain 
(non-infectious meningoencephalitis), nasal cavity (malignant 
nasal tumors), forefoot (malignant muscular tumors), and 
abdomen (malignant intestinal tumors). The clinical target 
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Fig. 2. Percent isodose distributions in nasal tumors (non-infectious
meningoencephalitis or necrotizing meningoencephalitis). (A 
and B) Axial (A) and sagittal (B) views using a 300 kV X-ray beam; 
(C and D) axial and sagittal (D) views using a 450 kV X-ray beam; 
and (E and F) axial (E) and sagittal (F) views using a 6 MV X-ray 
beam. Colored scale bars indicate isodose levels normalized to 
the prescribed dose.
Fig. 3. Percent isodose distributions in forefoot tumors 
(malignant muscular tumor or anaplastic rhabdomyosarcoma). 
(A and B) Axial (A) and sagittal (B) views using a 300 kV X-ray 
beam; (C and D) axial (C) and sagittal (D) views using a 450 kV
X-ray beam; and (E and F) axial (E) and sagittal (F) views using a
6 MV X-ray beam. Colored scale bars indicate isodose levels 
normalized to the prescribed dose. 
volume (CTV) was determined for each tumor, and the planning 
target volume (PTV) was defined as the CTV with margins of 
0.1 cm. The CTV was composed of demonstrated tumors and all 
other tissues presumed to be tumors, and the PTV included the 
CTV and an additional volume accounting for patient 
movements and setup inaccuracies [14,15]. Treatment plans 
were determined for application of three-dimensional 
conformal radiation therapy. In calculating doses, an 
inhomogeneity correction algorithm was applied to all 
treatment plans. For comparison, optimal plans based on the 
energy of the X-ray beams and tumor locations were designed. 
For example, plans for treating nasal and forefoot tumors with 
6 MV X-ray beams included three 15o wedges and 1.5 cm thick 
boluses, respectively, whereas plans for all other tumors did not 
include wedges and boluses. Detailed information on treatment 
plans for each tumor site and X-ray beam energy are presented 
in Table 1. The same conditions were used for planning 
treatments with the 300 kV and 450 kV X-ray beams and were 
imported into CorePLAN by using GATE software. For 
comparison purposes, treatment planning was normalized so 
that treatment with all three X-ray beam energies resulted in 
coverage of the tumor with the same radiation dose, defined as 
＞ 95% of the prescribed dose being delivered to the PTV.
For quantitative comparisons, conventional comparative 
tools, including dose-volume histograms (DVH) [1,10], 
radiation dose homogeneity index (HI) of the tumor, and the 
radiation dose conformity index (CI) of the tumor, were 
calculated and compared with the results obtained for the 300 
kV, 450 kV, and 6 MV X-ray beams. The DVH shows the 
relationship between radiation dose and tissue volume and is 
most frequently used to compare doses from different radiation 
treatments. The DVH column height represents the volume of 
the structure receiving greater than or equal to that dose. The 
DVH for each organ forms a single curve, providing 
quantitative information on the dose-volume relationship. 
Moreover, lower DVH column heights for normal organs 
indicate better radiation treatment.
HI is calculated using the formula: HI = (D2 – D98)/Dp × 100, 
where D2 and D98 are the doses received at 2% and 98% of the 
PTV, respectively, and Dp is the prescribed dose [31]. A lower 
HI therefore indicates better uniformity of the prescribed 
radiation dose to the tumor.
CI is calculated by using the formula: CI = PI/PTV, where PI 
corresponds to the prescription dose volume receiving doses 
above the prescribed dose [28]. A CI value close to one indicates 
that the prescribed dose was accurately delivered to the PTV. An 
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Fig. 4. Dose-volume histogram results for nasal tumors (malignant 
nasal tumor or transitional cell sarcoma) from the 300 kV, 450 kV, 
and 6 MV X-ray beams. Results are shown for (A) the planning 
target volume of the tumor, as well as for the (B) body, (C) brain, (D) 
left eye, (E) right eye, (F) left lens, and (G) right lens.
X-ray beam energy device with a lower HI (or CI) than another 
X-ray beam energy device is therefore clinically superior.
Results
Radiation doses at various depths for 300 kV, 450 kV, and 6 
MV X-ray beams
Fig. 1 shows the PDDs for the 300 kV and 450 kV X-ray 
beams, obtained by using GATE, and for the 6 MV X-ray beam, 
obtained by using CorePLAN. At a field size of 20 cm × 20 cm, 
the build-up depths, representing the distance between the 
surface dose and the maximum dose [24], were 0.4, 0.8, and 1.6 
cm for the 300 kV, 450 kV, and 6 MV X-ray beams, respectively, 
indicating that build-up distances were smaller for the 300 kV 
and 450 kV X-ray beams than for the 6 MV X-ray beam. In 
general, a greater build-up depth results in a greater skin sparing 
effect during radiotherapy. However, beams with a greater 
build-up depth also have a disadvantage, as they are less 
appropriate for the treatment of tumors at shallower depths. 
Compared with the 6 MV X-ray beam, the kilovoltage X-ray 
beams provided sharply lower radiation doses at depths of 0 to 
10 cm. This depth-associated reduction in radiation dose was 
greatest for the 300 kV X-ray beam, with the difference in doses 
at various depths being slight for the 300 kV and 450 kV X-ray 
beams. The 300 kV and 450 kV X-ray beams showed a 
maximum difference of 7.08% and an average difference of 
1.35%.
Results of treatment simulation using various X-ray beam 
energies
Figs. 2 and 3 show the simulation results for the treatment of 
nasal tumors and upper forefoot tumors, respectively, at various 
X-ray beam energies. A colored curve, often called the isodose, 
represents a contour area with the same radiation dose inside the 
animal. The colored scale bars for the various isodose 
boundaries are included in Figs. 2 and 3, respectively. The 
treatment simulation results were evaluated in the axial and 
sagittal planes after creating treatment plans using the 300 kV, 
450 kV, and 6 MV X-ray beams. Although the differences were 
not significant, the radiation doses to normal tissues and tumors 
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Table 2. Dosimetric comparisons of organs at risk in nasal tumor 
treatment plans using 300 kV, 450 kV, and 6 MV X-ray beams
Organ 300 kV 450 kV 6 MV
Body V30 (%) 9.8 9.9 9.2
V60 (%) 5.1 5.3 4.8
V90 (%) 2.4 2.3 2.3
Brain V30 (%) 10.7 11.1 10.8
V60 (%) 5.5 5.7 5.7
V90 (%) 2.3 2.4 3.0
Right eye V30 (%) 100.0 100.0 90.0
V60 (%) 62.4 55.8 42.0
V90 (%) 5.1 4.3 11.4
Left eye V30 (%) 76.1 76.1 70.3
V60 (%) 44.2 39.1 34.2
V90 (%) 1.8 1.8 8.8
Right lens V30 (%) 100.0 100.0 100.0
V60 (%) 70.0 51.3 0.0
V90 (%) 0.0 0.0 0.0
Left lens V30 (%) 100.0 100.0 94.4
V60 (%) 60.0 50.4 40.0
V90 (%) 0.0 0.0 6.7
Vx (%), the % volume receiving at least x% of the prescribed dose.
Fig. 5. Dose-volume histogram results 
for brain tumors (non-infectious 
meningoencephalitis or necrotizing 
meningoencephalitis) from the 300 kV, 
450 kV, and 6 MV X-ray beams. Results 
are shown for (A) the planning target 
volume of the tumor, as well as for the 
(B) body, (C) oral cavity, (D) brain, (E) 
left eye, (F) right eye, (G) left lens, and 
(H) right lens.
were better with the 6 MV X-ray beam than with the 300 kV and 
450 kV X-ray beams.
Fig. 4 presents a summary of the DVHs of the tumor (PTV), 
the whole body, and the adjacent important organs for the 
treatment of nasal tumors. Although treatment of nasal cancers 
with the 6 MV X-ray beam provided better DVH results for the 
PTV than the 300 kV and 450 kV X-ray beams, all three 
provided similar DVHs for the whole body and adjacent organs 
(brain, eye, and lens). Table 2 presents the detailed DVH results 
for whole body and organ regions adjacent to the nasal tumors 
(brain, eye, and lens) that the percent of volume receiving at 
least 30% (V30), 60% (V60), and 90% (V90) of the prescribed 
dose. Lower V30, V60, and V90 values for normal organs are 
indicative of better radiation therapy.
In contrast, all three X-ray beam energies provided similar 
DVH results for the brain tumors PTV (Fig. 5). Although the 
DVHs of the 6 MV X-ray beam to the body and adjacent organs 
(brain, oral cavity, eye, and lens) were lowest, those values did 
not differ significantly from those of the 300 kV and 450 kV 
X-ray beams, suggesting that the three energies provided 
similar radiation results for the treatment of brain tumors.
Table 3 shows the HI and CI results for the four types of 
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Table 3. Homogeneity and conformity indices for planned 
tumor volumes of four tumor sites when using 300 kV, 450 kV, 
and 6 MV X-ray beams
Tumor site Index 300 kV 450 kV 6 MV
Brain Homogeneity index   6.3   9.1   9.1
Conformity index   4.50   3.93   3.37
Nasal Homogeneity index 17.7 16.4   9.1
Conformity index   2.93   2.57   2.38
Forefoot Homogeneity index 15.6 18.9 10.0
Conformity index   1.19   1.17   1.17
Abdomen Homogeneity index 20.6 23.4   6.4
Conformity index   1.70   1.76   1.22
tumors. Whereas the 300 kV X-ray beam yielded the optimal 
(lowest) HI for the treatment of brain tumors, the 6 MV X-ray 
beam yielded optimal HI results for the treatment of nasal, 
forefoot, and abdominal tumors. In contrast, the 6 MV X-ray 
beam yielded optimal (lowest) CI results, regardless of the 
treatment site.
Discussion
The present study compared the results of 300 kV, 450 kV, and 
6 MV X-ray beams for radiotherapy of tumors in companion 
animals. The comparisons included assessment of radiation 
doses (via DVH evaluation) delivered to tumor and adjacent 
organs, as well as assessment of the associated HI and CI 
results.
The build-up distances for the 300 kV (0–0.4 cm) and 450 kV 
(0–0.8 cm) X-ray beams were much shorter than that for the 6 
MV X-ray beam (1.6 cm), which may result in weaker skin 
protection. Analyses based on DVHs and V30, V60, and V90 
doses suggested that all three X-ray beam energies yielded 
similar dose distributions when treating brain and nasal tumors. 
For brain tumors, the 300 kV X-ray beam yielded the optimal HI 
(6.3), whereas the 6 MV X-ray beam yielded the optimal CI 
(3.37). For the nasal, forefoot, and abdominal tumors, the 6 MV 
X-ray beam provided the optimal HI (9.1, 10.0, and 6.4, 
respectively) and CI (2.38, 1.17, and 1.22, respectively) values. 
The differences among the various beam energies for 
abdominal tumors may be associated with their relative depth; 
as well, abdominal tumors are larger (170.2 cm3) than brain 
(1.9 cm3), nasal (7.4 cm3), and forefoot (142.7 cm3) tumors.
Compared with the results of the kilovoltage X-ray beams, 
the megavoltage X-ray beam generally delivered lower doses to 
surrounding organs. These differences, however, were not 
statistically significant and may have negligible effect in the 
treatment of cancers in animals. The results indicate that 
radiotherapy using kilovoltage X-ray beams may be feasible in 
companion animals. Our results suggest that the manufacturing, 
management, and shielding advantages of kilovoltage X-ray 
beams could contribute to the more widespread use of 
radiotherapy for companion animals.
The present study was limited by the small number of tumors 
examined, suggesting the need for further research on the 
effects and effectiveness of kilovoltage X-ray beam treatment 
for companion animals.
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